Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
Ligand retains all Pelican commercial royalties and will own 49.9% of Primrose Bio, Inc. as a stand-alone private company with leading technologies in synthetic biologyLigand contributes $15 million in exchange for economic interest in select Primrose programsLigand improves cash expense outlook and raises EPS guida...
Source: pharmiweb.com
